Home > News > BioSante Pharmaceuticals Announces Positive Results
April 29th, 2004
BioSante Pharmaceuticals Announces Positive Results
Abstract:
BioSante Pharmaceuticals, Inc. today announced that a comparative preclinical study demonstrated its calcium phosphate nanotechnology-based vaccine adjuvant, BioVant(TM), may be more effective than aluminum salt derivatives, the only adjuvant currently approved by the Food and Drug Administration. The study was conducted in collaboration with the U.S. Centers for Disease Control and Prevention in a previously unannounced BioSante collaboration.
Source:
Businesswire
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||